Mazen Alsahli
531 Davis Dr, Newmarket, ON L3Y 6P5,
Canada
Research Article
Hypoglycemia with New –Generation Basal Analog Insulins: A Descriptive Critical Review
Author(s): Mazen Alsahli, James R Thrasher and John E GerichMazen Alsahli, James R Thrasher and John E Gerich
Optimizing the treatment of people with diabetes relies on balancing the benefits of glycemic control with the risk of hypoglycemia. Although insulin is essential for treating patients with type 1 diabetes mellitus (T1DM), patient and physician concerns regarding an increased risk of hypoglycemia can lead to delays in initiating insulin treatment in patients with type 2 diabetes mellitus (T2DM). This clinical inertia contributes to reduced glycemic control and poorer outcomes for patients. Advances in insulin agents have reduced the risk of hypoglycemia. In particular, the introduction of insulin glargine, the first basal analog insulin with a 24-hour glucose-lowering profile with no pronounced peak, represented a significant step towards achieving this goal. To further improve patient management, a number of insulin formulations and molecules are in development and are designed to h.. View More»
